---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-024095"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2026-05-18T12:56:23+00:00"
generated_at: "2026-05-18T13:01:31.891184+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Evofem Q1 net loss $5.5M ($0.04/sh) vs prior net income; sales rise to $0.9M

## Summary
- Net loss $5.5M ($0.04 per share) vs net income $1.0M ($0.01 per share) in Q1 2025.
- Net sales $0.9M, up ~12.5% from $0.8M in Q1 2025; driven by higher WAC and improved gross-to-net.
- Operating expenses $5.5M after excluding a one-time $5.6M R&D reduction from trade payables settlement.
- Entered distribution agreement for SOLOSEC in Sub-Saharan Africa with Clovis Davis Pharmaceuticals.
- UAE regulatory review ongoing; pricing certificates for PHEXX obtained; NIH-funded Phase 4 trial enrolling patients.

## SEC filing metadata
- accession: 0001493152-26-024095
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2026-05-18T12:56:23+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315226024095/0001493152-26-024095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315226024095/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-024095
- JSON: https://secwatch.observer/filing/0001493152-26-024095.json
- Plain text: https://secwatch.observer/filing/0001493152-26-024095.txt

## Key facts
- Earnings Releases
  Evofem Biosciences, Inc. reported the three months ended March 31, 2026 results: revenue $0.9 million, net income $5.5 million, EPS $(0.04) per basic and diluted share.
  - Period: the three months ended March 31, 2026
  - Revenue: $0.9 million
  - Net income: $5.5 million
  - EPS: $(0.04) per basic and diluted share
  - Result: reported results
  source text: For the three months ended March 31, 2026, net sales were $0.9 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618835/000149315226024095/0001493152-26-024095-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.